Oruka Therapeutics, Inc.

ORKASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 907654

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	—	—	$0.00	$0.00	$0.00
Research and Development Expense	$75.1M	$75.1M	$4.7M	$13.8M	$5.0M
Selling, General and Administrative Expense	—	—	—	—	—
Operating Expenses	$88.1M	$88.1M	$10.6M	$19.3M	$9.8M
Operating Income (Loss)	-$88.1M	-$88.1M	-$10.6M	-$19.3M	-$9.8M
Interest Expense	—	—	—	—	$9.0K
Nonoperating Income (Expense)	$4.4M	$4.4M	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$396.0M	$1.0K	$43.1M	$54.9M	$50.4M
Assets, Current	$376.9M	$1.0K	$42.7M	$54.4M	$50.0M
Cash and Cash Equivalents, at Carrying Value	$61.6M	$61.6M	$42.4M	$53.4M	$49.1M
Liabilities	$13.8M	$13.8M	$1.4M	$3.9M	$3.9M
Liabilities, Current	$13.0M	$13.0M	$1.1M	$3.5M	$3.5M
Accounts Payable, Current	—	—	$334.0K	$1.1M	$1.8M
Stockholders' Equity Attributable to Parent	$1.0K	$1.0K	$51.0M	$46.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$57.8M	-$57.8M	-$10.9M	-$18.8M	-$7.7M
Net Cash Provided by (Used in) Investing Activities	-$330.1M	-$330.1M	-$2.0K	-$43.0K	-$19.0K
Net Cash Provided by (Used in) Financing Activities	$449.5M	$449.5M	$0.00	$23.1M	$48.5M
Payments to Acquire Property, Plant, and Equipment	$189.0K	$189.0K	$2.0K	$43.0K	$19.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)